Agenus Gross Margin 2010-2022 | AGEN

Current and historical gross margin for Agenus (AGEN) over the last 10 years. The current gross profit margin for Agenus as of March 31, 2022 is %.
Agenus Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.31B $0.31B 98.71%
2021-12-31 $0.30B $0.29B 98.65%
2021-09-30 $0.31B $0.30B 98.70%
2021-06-30 $0.07B $0.07B 94.20%
2021-03-31 $0.09B $0.08B 95.29%
2020-12-31 $0.09B $0.09B 96.59%
2020-09-30 $0.09B $0.09B 97.83%
2020-06-30 $0.10B $0.10B 98.97%
2020-03-31 $0.09B $0.09B 100.00%
2019-12-31 $0.15B $0.15B 100.00%
2019-09-30 $0.12B $0.12B 100.00%
2019-06-30 $0.12B $0.12B 100.00%
2019-03-31 $0.12B $0.12B 100.00%
2018-12-31 $0.04B $0.04B 100.00%
2018-09-30 $0.04B $0.04B 100.00%
2018-06-30 $0.03B $0.03B 100.00%
2018-03-31 $0.02B $0.02B 100.00%
2017-12-31 $0.04B $0.04B 100.00%
2017-09-30 $0.04B $0.04B 100.00%
2017-06-30 $0.04B $0.04B 100.00%
2017-03-31 $0.04B $0.04B 100.00%
2016-12-31 $0.02B $0.02B 100.00%
2016-09-30 $0.03B $0.03B 100.00%
2016-06-30 $0.03B $0.03B 100.00%
2016-03-31 $0.03B $0.03B 100.00%
2015-12-31 $0.03B $0.03B 100.00%
2015-09-30 $0.02B $0.02B 100.00%
2015-06-30 $0.01B $0.01B 100.00%
2015-03-31 $0.01B $0.01B 100.00%
2014-12-31 $0.01B $0.01B 100.00%
2014-09-30 $0.01B $0.01B 100.00%
2014-06-30 $0.01B $0.01B 100.00%
2014-03-31 $0.00B $0.00B 100.00%
2013-12-31 $0.00B $0.00B 100.00%
2013-09-30 $0.00B $0.00B 100.00%
2013-06-30 $0.00B $0.00B 100.00%
2013-03-31 $0.00B $0.00B 75.00%
2012-12-31 $0.02B $0.02B 93.75%
2012-09-30 $0.02B $0.02B 93.75%
2012-06-30 $0.02B $0.02B 93.75%
2012-03-31 $0.02B $0.02B 100.00%
2011-12-31 $0.00B $0.00B 100.00%
2011-09-30 $0.00B $0.00B 100.00%
2011-06-30 $0.00B $0.00B 100.00%
2011-03-31 $0.00B $0.00B 100.00%
2010-12-31 $0.00B $0.00B 100.00%
2010-09-30 $0.00B $0.00B 100.00%
2010-06-30 $0.00B $0.00B 100.00%
2010-03-31 $0.00B $0.00B 100.00%
2009-12-31 $0.00B $0.00B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.554B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00